Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 10, 2018

Primary Completion Date

October 12, 2021

Study Completion Date

October 12, 2021

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

Efavaleukin Alfa

Efavaleukin Alfa will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.

DRUG

Placebo

The placebo will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.

Trial Locations (15)

10117

Charite Universitätsmedizin Berlin, Berlin

11021

Northwell Health, Great Neck

13003

Hopital Europeen Marseille, Marseille

16635

Altoona Center for Clinical Research, Duncansville

33180

Translational Clinical Research LLC, Aventura

36207

Pinnacle Research Group LLC, Anniston

59037

Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez, Lille

67091

Centre Hospitalier Universitaire de Strasbourg - Nouvel hopital civil, Strasbourg

75013

Hopital Pitie-Salpetriere, Paris

75231

Metroplex Clinical Research Center, Dallas

90211

Wallace Rheumatic Studies Center LLC, Beverly Hills

60-848

Clinical Research Center Spzoo Medic-R Spolka Komandytowa, Poznan

21-040

Tomasz Blicharski Lubelskie Centrum Diagnostyczne, Świdnik

00-874

Medycyna Kliniczna Marzena Waszczak - Jeka, Warsaw

51-124

Wojewodzki Szpital Specjalistyczny we Wroclawiu, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY